Sandoz Group AG
SDZ
Rank in Stocks
#579
Operating globally, Sandoz Group AG specializes in the development, production,... Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Share Price
$95.70
Market Cap
$41.41B
Change (1 day)
0.48%
Change (1 year)
58.13%
Country
CH
Trade Sandoz Group AG (SDZ)
Category
Healthcare
Revenue for Sandoz Group AG (SDZ)
Revenue in Oct 2026 TTM: 0
According to Sandoz Group AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sandoz Group AG from 2020 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $11.16B | 22.32% |
| 2024 | $9.12B | -8.60% |
| 2023 | $9.98B | 7.23% |
| 2022 | $9.31B | -3.84% |
| 2021 | $9.68B | 1.28% |
| 2020 | $9.56B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
